Antiemetic Therapy — CPB 0724 | AETNA Coverage Update

Aetna modified CPB 0724 covering antiemetic therapy, effective October 21, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its antiemetic therapy coverage policy under CPB 0724 Aetna system effective October 21, 2025. This policy governs antiemetic billing across chemotherapy administration codes (CPT 96401–96424 and beyond), radiation treatment delivery codes (CPT 77371–77425), and postoperative settings including sleeve gastrectomy (CPT 43775). The update refines medical necessity criteria for drugs like palonosetron (Aloxi), fosaprepitant dimeglumine (Emend), amisulpride (Barhemsys), and rolapitant (Varubi) — and if your team bills these agents without mapping to the right clinical pathway, you're looking at claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Antiemetic Therapy — CPB 0724
Policy Code	CPB 0724
Change Type	Modified
Effective Date	October 21, 2025
Impact Level	High
Specialties Affected	Oncology, Radiation Oncology, Anesthesiology, Surgery, Infusion Therapy
Key Action	Audit antiemetic drug selection and step-therapy documentation before billing against CPT 96401–96424 and 77371–77425

---

Aetna Antiemetic Therapy Coverage Criteria and Medical Necessity Requirements 2025

The real issue with this Aetna antiemetic coverage policy is step therapy. Aetna doesn't just ask whether a patient needs an antiemetic — it asks whether your team tried the right one first, in the right form, at the FDA recommended dose. Miss that documentation, and medical necessity falls apart on review.

Here's how the tiers work for cancer chemotherapy settings.

Palonosetron (Aloxi) and fosaprepitant dimeglumine (Emend) are medically necessary for two paths. First, prevention of acute nausea or vomiting with moderately or highly emetogenic chemotherapy — including high-dose cisplatin. Second, treatment of chemo-induced nausea from low or minimally emetogenic chemo, but only when IV granisetron (Kytril) or ondansetron (Zofran) has failed or is contraindicated at the FDA recommended dose.

That second path is the one billing teams get wrong. "Failed" is not a clinical impression. You need documented proof of an inadequate response to IV granisetron or ondansetron at FDA-recommended doses before Aetna will call palonosetron or Emend medically necessary for low-emetogenic regimens.

Granisetron (Kytril), extended-release granisetron (Sustol), and ondansetron (Zofran) IV are medically necessary for moderately and highly emetogenic chemo — including high-dose cisplatin — for both acute and delayed nausea and vomiting. For low or minimally emetogenic chemo, the step is earlier: IV formulations require documented failure of or contraindication to the oral forms first.

This is a classic "oral before IV" step-therapy structure. Make sure your documentation reflects it or your reimbursement on these agents is at risk.

Combined palonosetron and fosaprepitant gets its own bucket. Aetna covers this combination for high emetic risk patients who have failed a prior regimen of a steroid plus a 5-HT3 antagonist. That's a two-drug failure documented before you get to the combination.

Rolapitant (Varubi) and aprepitant (Cinvanti) are covered in combination with dexamethasone and a 5-HT3 serotonin receptor antagonist — given before IV antineoplastic therapy — for prevention of delayed nausea and vomiting. This applies to both moderate and high emetic risk chemotherapy. Adults only.

Akynzeo injection (fosnetupitant/palonosetron) with dexamethasone is covered for adults receiving highly emetogenic cancer chemotherapy — both acute and delayed nausea and vomiting prevention. The indication here is narrower: highly emetogenic only.

For radiation settings, the Aetna antiemetic coverage policy follows the same stepwise logic. IV granisetron or IV ondansetron are medically necessary for radiation-induced nausea and vomiting from total body irradiation (TBI) — but only when oral forms have failed or are contraindicated. Dolasetron mesylate (Anzemet) steps in after IV granisetron or IV ondansetron fail.

Postoperative coverage centers on amisulpride (Barhemsys) IV for adults 18 and older. Aetna draws a clean line between two uses. For PONV prevention, the dose is 5 mg IV at anesthesia induction — alone or combined with a non-dopaminergic antiemetic like ondansetron, dexamethasone, or betamethasone. For PONV treatment, the dose is 10 mg IV, but only for patients who received non-dopaminergic prophylaxis or received no prophylaxis at all. Document which indication you're billing. A 5 mg claim billed as treatment — or a 10 mg claim billed as prevention — will fail medical necessity review.

Prior authorization requirements are not fully detailed in the policy text, but the step-therapy structure implies payers will require step documentation on appeal or audit. Talk to your compliance officer before October 21, 2025, if your practice doesn't have a process for capturing prior-agent failure documentation at the time of administration.

---

Aetna Antiemetic Therapy Exclusions and Non-Covered Indications

The policy summary as provided does not detail a full experimental or non-covered list in the truncated text. However, the step-therapy structure itself creates functional non-coverage. If you skip the required prior agent, the higher-tier drug is not covered — regardless of clinical appropriateness.

The practical exclusions are:

If the full policy appendix adds additional exclusions under the ICD-10-based emetic risk tables, check the live policy at the Aetna CPB 0724 source for the complete criteria.

---

Coverage Indications at a Glance

---

Aetna Antiemetic Therapy Billing Guidelines and Action Items 2025

This is where antiemetic billing gets expensive if you're sloppy. The step-therapy requirements are real, and Aetna will use them on post-pay audit. Here's what to do before October 21, 2025.

Copy Action Items

If you're uncertain how this coverage policy maps to your specific payer mix or plan variants, loop in your compliance officer before the October 21, 2025, effective date. Step-therapy denials tend to come in clusters on post-pay audits — and they're expensive to chase on appeal without the right documentation infrastructure in place.

---

CPT, HCPCS, and ICD-10 Codes for Antiemetic Therapy Under CPB 0724

Covered CPT Codes (When Selection Criteria Are Met)

Note: The full policy data includes 206 total CPT codes and 146 total HCPCS codes. The codes listed above represent those explicitly provided in the source data. Access the complete code set at the full CPB 0724 policy on PayerPolicy.

Key ICD-10-CM Diagnosis Codes

The policy data references 32 ICD-10-CM codes but does not provide descriptions in the data extract above. Pull the complete ICD-10-CM list directly from the CPB 0724 Aetna policy source. These codes map to emetogenic risk levels and nausea/vomiting diagnoses that support medical necessity — you need them to build your claim documentation correctly.

---